Interoperability is becoming one of the most important bottlenecks in translational medicine. The reason for that is mainly that solutions for a single therapeutic process are usually segmented among the different phases of the health chain, going from diagnosis to therapy and eventually to public health in order to promote a healthier society through prevention rather than intervention.
Research and Innovation
The Idealist2018 project is funded by the European Commission under the Leading Industrial Enabling Technologies ICT theme, of Horizon2020 – Research & Innovation Framework Programme, under grant agreement no. 645216. Any opinions expressed in these pages are those of the author/organisation and do not necessarily reflect the views of the European Commission.